List of Excipients in Branded Drug PLASMANATE

PLASMANATE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 15, 2026

PLASMANATE is a 5% human plasma protein fraction solution used for plasma-volume replacement. Its formulation relies on human plasma proteins stabilized with sodium caprylate and N-acetyl-DL-tryptophan, with sodium chloride and Water for Injection as supporting excipients. The main commercial opportunities are supply-chain security, low-volume parenteral manufacturing, hospital-stock optimization, regional plasma-product distribution, and differentiated packaging rather than conventional reformulation.

What is PLASMANATE and how is it formulated?

PLASMANATE is Plasma Protein Fraction (Human), 5%, administered by intravenous infusion. The product is derived from pooled human plasma and contains albumin and globulin proteins. Grifols Therapeutics LLC is identified as the manufacturer on the U.S. product labeling. [1]

The formulation is designed to preserve protein integrity during manufacturing, storage, and administration.

Formulation element	Function	Commercial relevance
Human plasma protein fraction	Active biological component; provides oncotic and volume-expanding activity	Requires plasma collection, viral safety controls, protein purification, and cold-chain or controlled storage
Sodium caprylate	Protein stabilizer and fatty-acid ligand	Supports albumin stability and reduces aggregation risk
N-acetyl-DL-tryptophan	Protein stabilizer and antioxidant-type excipient	Protects against protein oxidation and denaturation during heat treatment
Sodium chloride	Tonicity and electrolyte adjustment	Supports intravenous compatibility
Water for Injection	Sterile vehicle	Requires parenteral-grade water and aseptic processing

PLASMANATE is not a simple synthetic small-molecule injection. The excipient system must be evaluated against protein aggregation, oxidation, precipitation, container interaction, visible and subvisible particles, and viral-inactivation conditions.

What excipients protect PLASMANATE stability?

The central excipient strategy is the use of caprylate and acetyltryptophan as dual stabilizers.

Sodium caprylate

Sodium caprylate binds to albumin and helps maintain its native conformation. In plasma-derived albumin and plasma-protein formulations, caprylate is commonly used to improve resistance to heat and other manufacturing stresses.

Commercial advantages include:

• Long-established use in licensed plasma-derived products.
• Compatibility with heat-treatment processes.
• Established analytical methods for assay and impurity monitoring.
• A relatively low regulatory barrier compared with novel protein stabilizers.

The primary development risks are residual-level control, interaction with filtration membranes, and changes in protein binding behavior during scale-up.

N-acetyl-DL-tryptophan

N-acetyl-DL-tryptophan is used as a stabilizer in human albumin and related plasma-protein products. It can reduce oxidative damage and support protein stability under thermal stress.

Its commercial value is linked to manufacturing robustness rather than patient-facing differentiation. A substitute stabilizer could create a new formulation platform, but it would also require comparative stability, toxicology, extractables and leachables, and regulatory bridging data.

Sodium chloride and Water for Injection

Sodium chloride supports tonicity and electrolyte control. Water for Injection provides the sterile vehicle. These components are operationally familiar but remain important to product quality because changes in ionic strength can affect protein solubility, aggregation, and infusion tolerability.

A reformulation that changes sodium concentration would require evaluation of:

• Osmolality.
• Infusion-site tolerability.
• Compatibility with common intravenous fluids.
• Protein stability after dilution.
• Clinical use in patients with sodium or fluid restrictions.

What formulation patents protect PLASMANATE?

Public PLASMANATE labeling identifies the product composition and manufacturing controls but does not establish an active Orange Book patent estate. PLASMANATE is a biologic plasma-derived product, so the small-molecule Orange Book framework does not provide the primary exclusivity record.

Potential intellectual-property categories include:

1. Plasma fractionation processes.
2. Heat-treatment and viral-inactivation methods.
3. Stabilizer combinations.
4. Protein purification and filtration.
5. Container-closure systems.
6. Low-protein-loss membrane systems.
7. Batch-release and impurity-control methods.
8. Manufacturing processes that improve yield or reduce aggregation.

The commercial importance of these rights depends on claim scope and remaining patent term. A competitor may avoid a formulation patent by retaining caprylate and acetyltryptophan while changing concentration, processing conditions, container materials, or purification steps.

A current product-specific patent list cannot be inferred from the PLASMANATE label. Patent searches should distinguish between patents assigned to Grifols, predecessor entities, plasma fractionation technology suppliers, and expired foundational albumin-process patents.

What is the FDA regulatory status of PLASMANATE?

PLASMANATE is regulated as a licensed human blood-derived biological product. FDA labeling identifies the product as Plasma Protein Fraction (Human), 5%. [1] The product is subject to biologic manufacturing controls covering donor screening, plasma testing, viral reduction, protein purification, sterility, potency, and lot release.

Orange Book status

PLASMANATE is not expected to have an Orange Book listing comparable to a conventional tablet or small-molecule injection. The Orange Book primarily lists approved drug products and associated patents under the Hatch-Waxman framework. Biologic exclusivity and biosimilar competition are tracked through FDA biologics mechanisms, including the Purple Book. [2]

Paragraph IV challenges

A conventional Paragraph IV abbreviated new drug application strategy is generally not the principal pathway for a plasma-derived biologic. A competitor would more likely require:

• A full biologics license application.
• A biosimilar application under section 351(k), if the product is eligible and FDA accepts the reference-product framework.
• A product-specific license supported by manufacturing, clinical, and nonclinical evidence.

The practical result is a higher entry burden than for an ordinary generic injectable.

When does PLASMANATE lose exclusivity?

No reliable public source cited here establishes a single current PLASMANATE exclusivity-loss date. The relevant barriers are likely to be regulatory and manufacturing-based rather than a single Orange Book patent expiration.

Regulatory exclusivity

For biologics, the Biologics Price Competition and Innovation Act provides reference-product exclusivity rules, including a 12-year period after first licensure for qualifying reference products, subject to statutory limitations. [3] Older plasma-derived products may have complex histories involving prior licenses, supplements, predecessor products, and regulatory transitions.

Patent exclusivity

Patent protection may cover manufacturing or formulation methods rather than the product name itself. A competitor must evaluate:

• Earliest effective filing date.
• Patent term adjustment.
• Patent term extension.
• Continuation and divisional applications.
• Terminal disclaimers.
• Claim overlap with plasma fractionation processes.

Manufacturing exclusivity

Manufacturing capacity can be more difficult to replicate than the formulation. A new entrant needs qualified plasma supply, validated viral-clearance steps, large-scale fractionation equipment, sterile filling capacity, and a sufficient history of lot consistency.

How strong is the PLASMANATE patent estate?

The effective protection profile is best characterized as process- and manufacturing-dependent, not as a clearly defined product patent estate.

Protection category	Likely strength	Main entry issue
Basic caprylate/acetyltryptophan formulation	Low to moderate if broadly disclosed in prior art	Difficult to obtain broad new claims over established stabilizers
Specific stabilizer concentrations	Moderate	Requires precise claim construction and freedom-to-operate analysis
Plasma fractionation process	Moderate to strong	Process scale, yield, purity, and viral safety may be difficult to replicate
Heat-treatment method	Moderate	Prior art may limit claim breadth
Container-closure configuration	Low to moderate	Can often be designed around
Plasma sourcing and donor network	Strong commercial barrier	Not a conventional patent barrier, but difficult to reproduce
Analytical release methods	Low as standalone IP	May protect know-how more effectively than patents

Trade secrets may provide greater practical protection than formulation patents. Process parameters, fractionation yields, impurity profiles, filtration conditions, and lot-release specifications are difficult to reconstruct from public labeling.

What commercial opportunities exist in PLASMANATE excipients?

Excipient supply and dual sourcing

Manufacturers of pharmaceutical-grade sodium caprylate and N-acetyl-DL-tryptophan can target plasma-derived protein manufacturers with qualified dual-source programs. The opportunity depends on:

• Compendial or equivalent quality.
• Low bioburden and endotoxin.
• Trace-metal control.
• Consistent residual-solvent profile.
• Documentation for change control.
• Supply continuity during global logistics disruptions.

A supplier that can provide validated, sterile or low-bioburden excipient grades may command higher value than a commodity chemical supplier.

Stabilizer replacement

Alternative stabilizers could reduce oxidation, improve heat stability, or simplify downstream purification. Candidate development areas include:

• Amino-acid-based stabilizer systems.
• Carbohydrate or polyol combinations.
• Antioxidant systems with low protein-binding interference.
• Lower-residue formulations.
• Stabilizers compatible with lyophilized plasma proteins.

The regulatory burden is significant because a new stabilizer changes the product’s impurity profile and may alter protein structure. The strongest opportunity is likely a platform stabilizer validated across several plasma-derived products, not a PLASMANATE-only formulation.

Container and delivery systems

PLASMANATE is supplied as an injectable solution, creating opportunities in:

• Low-sorption polymer bags.
• Break-resistant presentations.
• Ready-to-use infusion containers.
• Smaller-volume units for emergency departments and ambulances.
• Tamper-evident packaging.
• Improved overwraps for oxygen and moisture protection.

Packaging changes can improve inventory handling without altering the protein formulation. They still require container-closure integrity, particulate, extractables and leachables, stability, and shipping studies.

Hospital inventory optimization

PLASMANATE can be positioned for facilities that need plasma-volume expansion but face constraints involving:

• Blood-component inventory.
• Albumin availability.
• Emergency fluid protocols.
• Storage space.
• Product wastage from low utilization.
• Regional shortages of plasma-derived therapies.

Commercial value depends on product availability, price relative to albumin and crystalloid alternatives, and institutional protocols.

How does PLASMANATE compare with albumin and crystalloid products?

Attribute	PLASMANATE	Human albumin 5%	Isotonic crystalloid
Product type	Plasma protein fraction	Purified albumin	Synthetic electrolyte solution
Protein composition	Albumin plus globulins	Predominantly albumin	No protein
Plasma-derived	Yes	Yes	No
Manufacturing complexity	High	High	Lower
Viral-safety burden	High	High	Low
Formulation differentiation	Stabilizer and protein-composition focused	Concentration, excipients, packaging	Electrolyte composition and additives
Biosimilar complexity	Potentially high	High	Generally not relevant
Supply constraint	Plasma and fractionation capacity	Plasma and fractionation capacity	Raw materials and sterile filling
Main commercial advantage	Broader plasma-protein composition	Defined albumin concentration	Low cost and broad availability

PLASMANATE may compete with albumin in selected volume-expansion settings, but it does not have the same protein composition or clinical positioning. Crystalloids remain a lower-cost alternative in many settings, although they do not provide plasma proteins.

What generic, biosimilar, and launch risks exist?

A direct generic launch is unlikely to follow the standard ANDA model. A competitor would face several barriers:

1. Demonstrating comparable protein composition.
2. Establishing equivalent physicochemical properties.
3. Reproducing viral-clearance performance.
4. Securing a reliable human plasma supply.
5. Producing consistent lots at commercial scale.
6. Establishing clinical comparability where FDA requires it.
7. Qualifying a sterile container-closure system.
8. Maintaining pharmacovigilance and traceability.

The most credible competitive scenarios are:

• A new plasma-protein product with a different license.
• A biosimilar or follow-on application if FDA accepts the reference-product pathway.
• Regional competition from established plasma fractionators.
• Hospital substitution by albumin or crystalloids.
• Product switching caused by supply shortages rather than patent expiration.

Which companies could challenge PLASMANATE commercially?

Competition is most likely to come from manufacturers with existing plasma collection and fractionation networks. Relevant competitor groups include:

• Grifols.
• CSL Behring.
• Takeda.
• Kedrion.
• Octapharma.
• China-based plasma fractionators with domestic manufacturing capacity.
• Regional human-albumin and plasma-protein manufacturers.

The competitive advantage is usually determined by plasma access, fractionation yield, regulatory history, and hospital contracting. Excipient cost alone is unlikely to determine market leadership.

What litigation and settlement risks affect PLASMANATE?

No litigation or settlement agreement is established in the sources cited for this report as a current, product-specific barrier to PLASMANATE competition.

Potential disputes could arise over:

• Process patents.
• Plasma sourcing and donor-network arrangements.
• Manufacturing know-how.
• Trademark rights.
• Regulatory exclusivity.
• Biosimilar interchangeability or labeling.
• Product liability and viral-safety claims.
• Supply contracts and hospital tenders.

Because a direct Paragraph IV pathway is not the central route, litigation risk is more likely to involve process patents, biologic licensing, or commercial contracting than a standard generic patent challenge.

What geographic opportunities exist for PLASMANATE?

The strongest geographic opportunities are markets with:

• Established plasma-collection systems.
• Demand for plasma-volume replacement.
• Limited albumin supply.
• Reliable cold-chain and hospital distribution.
• Local regulatory pathways for plasma-derived products.
• Government procurement programs.

The United States and Europe have demanding plasma-product requirements but established reimbursement and hospital infrastructure. Emerging markets may offer volume growth but impose higher risks involving plasma collection, regulatory classification, local manufacturing, import controls, and pricing.

A regional manufacturing strategy can reduce shipping costs and improve supply reliability, but local fractionation may require technology transfer, donor-network development, and multi-year regulatory qualification.

Key Takeaways

• PLASMANATE is a 5% human plasma protein fraction solution, not a conventional small-molecule injectable.
• Sodium caprylate and N-acetyl-DL-tryptophan are the core stabilizing excipients.
• The strongest commercial barriers are plasma supply, fractionation capability, viral safety, and sterile manufacturing.
• Orange Book and Paragraph IV analysis is less useful than biologic-license, process-patent, and manufacturing analysis.
• A current, product-specific patent expiration date is not established by the cited public sources.
• The best excipient opportunities involve qualified dual sourcing, stabilizer platforms, low-sorption containers, and ready-to-use packaging.
• Direct generic entry is unlikely to be straightforward. Competition is more likely to come from plasma-derived biologic manufacturers, albumin suppliers, and hospital substitution.
• Process know-how and supply infrastructure may provide greater practical protection than the basic stabilizer formulation.

FAQs

Is PLASMANATE the same as 5% albumin?

No. PLASMANATE contains plasma protein fraction with albumin and globulin proteins. A 5% albumin product is predominantly albumin and has a different protein composition.

Can sodium caprylate be replaced in PLASMANATE?

Potentially, but replacement would require comparative stability, protein-structure, impurity, container-compatibility, safety, and regulatory studies.

Does PLASMANATE have an Orange Book patent listing?

PLASMANATE is a biologic plasma-derived product, so its protection is not expected to be represented through the conventional Orange Book patent-listing model.

Is a PLASMANATE biosimilar commercially feasible?

A follow-on or biosimilar-type product may be feasible in principle, but the mixed-protein composition, plasma sourcing, viral safety, and manufacturing comparability requirements create substantial development risk.

What is the most attractive excipient opportunity linked to PLASMANATE?

The strongest opportunity is a qualified, scalable stabilizer and packaging platform that improves supply continuity or protein stability across multiple plasma-derived products.

References

1. DailyMed. (n.d.). PLASMANATE: Plasma Protein Fraction (Human), 5% solution, prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
4. U.S. Food and Drug Administration. (2020). Questions and answers on biosimilar development and the BPCI Act.
5. U.S. Pharmacopeia. (n.d.). General chapter <1047>: Ancillary materials for cell, gene, and tissue-engineered products.
6. Grifols. (n.d.). Plasma-derived medicines and plasma fractionation information.